Review article: remission rates achievable by current therapies for inflammatory bowel disease.
about
Low dose naltrexone for induction of remission in Crohn's diseaseLow dose naltrexone for induction of remission in Crohn's diseaseVedolizumab for the treatment of ulcerative colitis and Crohn's diseaseStem cell-based therapies in inflammatory bowel disease: promises and pitfallsVedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel diseaseAdvances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2Review article: anti-adhesion therapies for inflammatory bowel diseaseAltered colonic mucosal Polyunsaturated Fatty Acid (PUFA) derived lipid mediators in ulcerative colitis: new insight into relationship with disease activity and pathophysiologyAdverse events in IBD: to stop or continue immune suppressant and biologic treatmentInhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis.Clinical pharmacology of AMG 181, a gut-specific human anti-α4β7 monoclonal antibody, for treating inflammatory bowel diseases.Intestinal fibrosis is reduced by early elimination of inflammation in a mouse model of IBD: impact of a "Top-Down" approach to intestinal fibrosis in miceOptimizing the use of anti-tumor necrosis factor in the management of patients with Crohn's disease.Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases.Matricellular Protein Periostin Mediates Intestinal Inflammation through the Activation of Nuclear Factor κB Signaling.STAT1, STAT6 and adenosine 3',5'-cyclic monophosphate (cAMP) signaling drive SOCS3 expression in inactive ulcerative colitis.Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis.JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokinesNilotinib-mediated mucosal healing in a rat model of colitis.Fermented Pueraria Lobata extract ameliorates dextran sulfate sodium-induced colitis by reducing pro-inflammatory cytokines and recovering intestinal barrier function.Systematic review: the role of tacrolimus in the management of Crohn's disease.Crohn's disease and the mycobacterioses: a quarter century later. Causation or simple association?Mucosal healing with anti-TNF antibodies.Ulcerative colitis: prevention of relapse.Immunomodulators in inflammatory bowel disease: an emerging role for biologic agents.Towards personalized care in IBD.Mycophenolate mofetil therapy in the management of inflammatory bowel disease--a retrospective case series and review.TNF blocking therapies and immunomonitoring in patients with inflammatory bowel diseaseInflammatory bowel disease meta-evidence and its challenges: is it time to restructure surgical research?Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease.Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.Interleukin-27 as a Novel Therapy for Inflammatory Bowel Disease: A Critical Review of the Literature.Recombinant human MFG-E8 ameliorates colon damage in DSS- and TNBS-induced colitis in mice.Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis.Systemic Chemokine Levels with "Gut-Specific" Vedolizumab in Patients with Inflammatory Bowel Disease-A Pilot StudySteroid-sparing strategies in the management of ulcerative colitis: efficacy of leukocytapheresis.The Vagus Nerve in the Neuro-Immune Axis: Implications in the Pathology of the Gastrointestinal Tract.Pepsin-pancreatin hydrolysis reduced the ability of lunasin-enriched material to inhibit activation of the inflammasomes in THP-1 human macrophages.Gp96 Peptide Antagonist gp96-II Confers Therapeutic Effects in Murine Intestinal Inflammation.Suppression Colitis and Colitis-Associated Colon Cancer by Anti-S100a9 Antibody in Mice.
P2860
Q24200319-F4C62C61-3945-4C5C-9269-7576DA159B0EQ24201218-613B2335-F742-4AF4-A3D0-2C319B6F1A28Q24630083-19268374-40D4-4E48-AA95-9DC84A49DAD2Q26745715-6CE5EF80-3B87-410C-A4D3-7687EE8D8FDBQ26752768-B7430201-7065-4FA0-AAA5-DCAFAF74CC76Q26798299-1DACB04C-DE0C-4D52-8B71-96C2C6CB6E9DQ26999705-9F8367D5-644C-4C0B-8334-7B37B5CCEEFDQ28534532-CA04FD8D-B562-4251-B699-E4C0247C8F55Q34073191-E88FF389-A037-4291-A3C7-62263B5EF5EBQ34381832-708B4312-10F3-4F7C-B4E5-2193C33366F2Q34635522-3C0E8B9F-8CD5-42FA-AA2D-C4CDAAA32102Q35510528-9928FF4A-4B11-418E-BE01-3AE7E4B02DC6Q35561386-57683A73-78F1-4B04-B053-0A7852ADA9E6Q35572174-126582DF-B6CD-4534-8DD0-B38E74ABED36Q35927164-2E995506-8876-4586-800F-80C2A203E43CQ36498298-BE27DA21-C6A1-4024-A473-D5FF7AA1DFA2Q36689512-B92BEDA2-60A6-4821-A667-5AF3C62E170CQ37148745-1786E6C5-4455-4CBA-ACE9-74298F3FE54DQ37208138-CE5A184B-CCE7-464A-8D00-EF947AD6CCB9Q37325113-AD3E7E0B-3CCB-48B3-9A3A-BBFC794F85F3Q37945747-6E19F307-3AFB-4C6D-ACFB-0B4D0923251AQ37975540-252AE081-3D05-49FF-AB83-10F502F2B0B7Q38050881-B0C5ADC7-D805-42FA-B713-24AD2F6D020AQ38103628-07893D50-FFEB-41D4-94B7-F26650A1DBF0Q38113159-53CB5D97-A6A2-47CC-BBC3-A5F31E15B799Q38171924-FFE653C4-25C9-4D57-97F0-29AA22EB667FQ38186168-D2A704B5-E236-481F-8BA1-1529F21C6EE3Q38206507-6ED84CB7-D47C-44F0-8151-88707A74B7BBQ38302725-7D9DE966-DD0C-4EB1-B714-B2B524D3A8D1Q38413494-74A51673-2B44-4BA5-A0AF-C97F9BF7E6D9Q38822920-63D222C7-28BA-45F0-909A-D612B8597DB4Q38848936-B7FB02FA-A01B-407E-BE02-056387F3F1D9Q38902205-22C23937-E2DD-46F3-9F18-4EE6B577FAAEQ39012932-C9D48FC2-6E09-4058-9A1D-E1362922A599Q41574652-399B09C3-0FA4-419B-8AFD-BD781D676F25Q42361175-10E094A5-5B6B-4934-84DE-9F0EA9BB0429Q45040278-8ECE99E4-8A1D-433E-85F0-A463E9AB40D3Q46271046-AA8909DA-D8A2-4CBB-B1F6-F78E5469DB1EQ47221352-E80DBFA3-66BC-4662-82D1-C601ECC10449Q49316629-6B4CF2D9-CA84-4354-859A-26888B487830
P2860
Review article: remission rates achievable by current therapies for inflammatory bowel disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Review article: remission rate ...... or inflammatory bowel disease.
@en
Review article: remission rate ...... or inflammatory bowel disease.
@nl
type
label
Review article: remission rate ...... or inflammatory bowel disease.
@en
Review article: remission rate ...... or inflammatory bowel disease.
@nl
prefLabel
Review article: remission rate ...... or inflammatory bowel disease.
@en
Review article: remission rate ...... or inflammatory bowel disease.
@nl
P2860
P1476
Review article: remission rate ...... or inflammatory bowel disease.
@en
P2093
L Peyrin-Biroulet
P2860
P304
P356
10.1111/J.1365-2036.2011.04599.X
P407
P577
2011-02-15T00:00:00Z